Jim Simons In8 Bio, Inc. Transaction History

Renaissance Technologies LLC

  • $63.1 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$0.95 - $1.69 $94,598 - $168,285
99,577 Added 508.62%
119,155 $141,000
Q4 2023

Feb 13, 2024
BUY
$0.69 - $2.34 $13,508 - $45,812
19,578 New
19,578 $27,000
Q2 2023

Aug 11, 2023
BUY
$1.05 - $3.24 $22,785 - $70,308
21,700 New
21,700 $33,000

Others Institutions Holding INAB

# of Institutions
27
Shares Held
7.62M
Call Options Held
0
Put Options Held
0
View Full List

About IN8BIO, INC.

INAB Quotes by TradingView
  • Ticker INAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,502,200
  • Market Cap $5.64M
  • Description
  • IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...
More about INAB
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email